Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Human Papillomavirus vaccine · 1 trial · 1 indication
For this trial, the primary endpoint is high-grade squamous intraepithelial lesions (HSIL) or atypical squamous cells suggestive of HSIL found on cervical cytology, or HSIL found on cervical biopsy specimens at either the week 26 or week 52 visit.
| Arm | Type | Description |
|---|---|---|
| Human Papillomavirus vaccine | EXPERIMENTAL | Participants receive the experimental quadrivalent Human Papillomavirus vaccine at entry, week 4 and week 26. |
| Saline placebo | PLACEBO_COMPARATOR | The participants receive saline placebo at entry, week 4 and week 26. |
| Name | Type | Description |
|---|---|---|
| Human Papillomavirus vaccine | BIOLOGICAL | The participants receive the qHPV vaccine at entry, week 4 and week 26 |
Inclusion Criteria: 1. HIV infection 2. Women aged ≥ 18 years. 3. Cervical HSIL on biopsy (i.e. CIN2 and/or CIN3) 4. For participants of reproductive potential, negative serum or urine pregnancy test 5. All study participants must agree not to participate in a conception process (e.g., active attem...
Human Papillomavirus vaccine is being studied for use in Cervical High Grade Squamous Intraepithelial Lesion, a precancerous condition of the cervix. It is an investigational therapy in Phase 2 clinical development, evaluated as a treatment to improve responses to LEEP procedures in patients with this condition.
Human Papillomavirus vaccine is developed by Merck & Company, Inc., a biopharmaceutical company traded on the New York Stock Exchange under the ticker symbol MRK. The company is conducting clinical research on this vaccine for the treatment of Cervical High Grade Squamous Intraepithelial Lesion.
Human Papillomavirus vaccine is in Phase 2 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still being evaluated in clinical trials for safety and efficacy in treating Cervical High Grade Squamous Intraepithelial Lesion.
Human Papillomavirus vaccine is being studied in clinical trial NCT01928225, titled 'Randomized, Double Blind Trial of the Quadrivalent HPV Vaccine to Improve Responses to LEEP Treatment of Cervical HSIL.' This Phase 2 trial has been completed and enrolled 180 female participants aged 18 years and older.
Human Papillomavirus vaccine is a monoclonal antibody modality designed to target human papillomavirus. It is being evaluated for its ability to improve responses to LEEP treatment in patients with Cervical High Grade Squamous Intraepithelial Lesion, a condition associated with HPV infection.
Human Papillomavirus vaccine is referred to as the quadrivalent HPV vaccine in clinical trial NCT01928225. This investigational vaccine is being studied for its potential to improve responses to LEEP treatment in patients with Cervical High Grade Squamous Intraepithelial Lesion.